SCHEMBL6448801

SCHEMBL6448801

C[C@@H](Br)CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3714954 1.00
SCHEMBL364463 1.00
Hydrochloric Acid SCHEMBL7730368 0.97
SCHEMBL11331701 0.78 CACNA2D1 (0.40)
SCHEMBL4745901 0.78
SCHEMBL7957995 0.78 ALDH1A1 (0.38)
SCHEMBL1396082 0.77
SCHEMBL28811052 0.77
SCHEMBL30155026 0.77
SCHEMBL6462670 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1594366-A2 FAT SUBSTITUTES Encore Pharmaceuticals, Inc (US) 2005-11-16 EP disclosed
EP-1592415-A2 THERAPEUTICALLY ACTIVE COMPOUNDS Encore Pharmaceuticals, Inc (US) 2005-11-09 EP disclosed
US-20040152777-A1 Therapeutically active compounds ENCORE PHARMACEUTICALS, INC. 2004-08-05 US disclosed
WO-2004064761-A2 THERAPEUTICALLY ACTIVE COMPOUNDS ENCORE PHARMACEUTICALS, INC. (US) 2004-08-05 WO disclosed
US-20040151758-A1 Fat substitutes ENCORE PHARMACEUTICALS, INC. 2004-08-05 US disclosed
WO-2004064539-A2 FAT SUBSTITUTES ENCORE PHARMACEUTICALS, INC. (US) 2004-08-05 WO disclosed
US-20020042055-A1 Alteration of hydrolase genes and screening of the resulting libraries for the ability to catalyze specific reactions MAXYGEN, INC. 2002-04-11 US disclosed
WO-2001046476-A1 ALTERATION OF HYDROLASE GENES AND SCREENING OF THE RESULTING LIBRARIES FOR THE ABILITY TO CATALYZE SPECIFIC REACTIONS MAXYGEN, INC. (US) 2001-06-28 WO disclosed